Literature DB >> 9858894

Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors.

E Eigenbrodt1, F Kallinowski, M Ott, S Mazurek, P Vaupel.   

Abstract

The interaction between glycolysis, glutaminolysis and tumor growth in WAG/Fra rnu/rnu rats has been investigated. Small tumors are characterized by a low conversion of glucose to lactate whereas the conversion of glutamine to lactate is high. In medium sized tumors the flow of glucose to lactate as well as oxygen utilization are increased whereas glutamine and serine consumption are reduced. At this stage the tumor cells start with glutamate and alanine production. Large tumors are characterized by a low oxygen and glucose supply but a high glucose and oxygen utilization rate. The conversion of glucose to glycine, alanine, glutamate, glutamine, and proline reaches high values and the amino acids are released. Pyruvate kinase increases with tumor weight and is positively correlated with an increase in glucose and oxygen utilization. The shift from glutamate consumption to glutamate production is correlated with an increase in glutamate dehydrogenase and glutamate oxaloacetate transaminase activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858894

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

Review 1.  Human pyruvate kinase M2: a multifunctional protein.

Authors:  Vibhor Gupta; Rameshwar N K Bamezai
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

2.  The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.

Authors:  K Koss; R F Harrison; J Gregory; S J Darnton; M R Anderson; J A Z Jankowski
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

Review 3.  Oncogenic viruses and tumor glucose metabolism: like kids in a candy store.

Authors:  Evan Noch; Kamel Khalili
Journal:  Mol Cancer Ther       Date:  2012-01       Impact factor: 6.261

4.  Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex.

Authors:  S Mazurek; W Zwerschke; P Jansen-Dürr; E Eigenbrodt
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

5.  Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.

Authors:  Maurizio Ventrucci; Antonio Cipolla; Chiara Racchini; Riccardo Casadei; Patrizia Simoni; Lucio Gullo
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

6.  Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia.

Authors:  Mark M Aloysius; Abed M Zaitoun; Timothy E Bates; Abdulkader Albasri; Mohammad Ilyas; Brian J Rowlands; Dileep N Lobo
Journal:  BMC Cancer       Date:  2009-09-15       Impact factor: 4.430

7.  Disrupting Na⁺, HCO₃⁻-cotransporter NBCn1 (Slc4a7) delays murine breast cancer development.

Authors:  S Lee; T V Axelsen; A P Andersen; P Vahl; S F Pedersen; E Boedtkjer
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

8.  Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma.

Authors:  Xing-chen Peng; Feng-ming Gong; Yu-wei Zhao; Liang-xue Zhou; Ying-wei Xie; Hong-li Liao; Hong-jun Lin; Zhi-yong Li; Ming-hai Tang; Ai-ping Tong
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

9.  Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer.

Authors:  P D Hardt; S Mazurek; M Toepler; P Schlierbach; R G Bretzel; E Eigenbrodt; H U Kloer
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

10.  Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.

Authors:  Leonor Puchades-Carrasco; Eloisa Jantus-Lewintre; Clara Pérez-Rambla; Francisco García-García; Rut Lucas; Silvia Calabuig; Ana Blasco; Joaquín Dopazo; Carlos Camps; Antonio Pineda-Lucena
Journal:  Oncotarget       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.